
Karl J. Puttlitz
Examiner (ID: 12924, Phone: (571)272-0645 , Office: P/1671 )
| Most Active Art Unit | 1621 |
| Art Unit(s) | 1671, 1621, 1204, 1646, 1642 |
| Total Applications | 2355 |
| Issued Applications | 1616 |
| Pending Applications | 153 |
| Abandoned Applications | 628 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 18492279
[patent_doc_number] => 11697690
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-07-11
[patent_title] => Site-specific glycoengineering of targeting moieties
[patent_app_type] => utility
[patent_app_number] => 17/215674
[patent_app_country] => US
[patent_app_date] => 2021-03-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 82
[patent_figures_cnt] => 114
[patent_no_of_words] => 34432
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 107
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17215674
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/215674 | Site-specific glycoengineering of targeting moieties | Mar 28, 2021 | Issued |
Array
(
[id] => 17213172
[patent_doc_number] => 20210346508
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-11-11
[patent_title] => ANTI-HER2 BIPARATOPIC ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
[patent_app_type] => utility
[patent_app_number] => 17/210081
[patent_app_country] => US
[patent_app_date] => 2021-03-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 34706
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -44
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17210081
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/210081 | Anti-HER2 biparatopic antibody-drug conjugates and methods of use | Mar 22, 2021 | Issued |
Array
(
[id] => 18619193
[patent_doc_number] => 11752215
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-09-12
[patent_title] => Targeting tumor cells with chemotherapeutic agents conjugated to anti-matriptase antibodies by in vivo cleavable linking moieties
[patent_app_type] => utility
[patent_app_number] => 17/200136
[patent_app_country] => US
[patent_app_date] => 2021-03-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 19
[patent_figures_cnt] => 28
[patent_no_of_words] => 14371
[patent_no_of_claims] => 9
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 283
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17200136
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/200136 | Targeting tumor cells with chemotherapeutic agents conjugated to anti-matriptase antibodies by in vivo cleavable linking moieties | Mar 11, 2021 | Issued |
Array
(
[id] => 18994617
[patent_doc_number] => 11911434
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-02-27
[patent_title] => Stable antibody-drug conjugate, preparation method therefor, and use thereof
[patent_app_type] => utility
[patent_app_number] => 17/180412
[patent_app_country] => US
[patent_app_date] => 2021-02-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 30
[patent_figures_cnt] => 76
[patent_no_of_words] => 13076
[patent_no_of_claims] => 8
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 17
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17180412
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/180412 | Stable antibody-drug conjugate, preparation method therefor, and use thereof | Feb 18, 2021 | Issued |
Array
(
[id] => 16899013
[patent_doc_number] => 20210177929
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-06-17
[patent_title] => NEW STABLE ANTIBODY-DRUG CONJUGATE, PREPARATION METHOD THEREFOR, AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/180645
[patent_app_country] => US
[patent_app_date] => 2021-02-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13005
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17180645
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/180645 | Stable antibody-drug conjugate, preparation method therefor, and use thereof | Feb 18, 2021 | Issued |
Array
(
[id] => 16900635
[patent_doc_number] => 20210179551
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-06-17
[patent_title] => PROCESS FOR PRODUCING ALKALI TAURINATE
[patent_app_type] => utility
[patent_app_number] => 17/176326
[patent_app_country] => US
[patent_app_date] => 2021-02-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6114
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -2
[patent_words_short_claim] => 90
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17176326
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/176326 | PROCESS FOR PRODUCING ALKALI TAURINATE | Feb 15, 2021 | Abandoned |
Array
(
[id] => 18575524
[patent_doc_number] => 11732038
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-08-22
[patent_title] => Conjugates comprising cell-binding agents and cytotoxic agents
[patent_app_type] => utility
[patent_app_number] => 17/174911
[patent_app_country] => US
[patent_app_date] => 2021-02-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 41
[patent_figures_cnt] => 45
[patent_no_of_words] => 42492
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 169
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17174911
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/174911 | Conjugates comprising cell-binding agents and cytotoxic agents | Feb 11, 2021 | Issued |
Array
(
[id] => 18978794
[patent_doc_number] => 11903948
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-02-20
[patent_title] => Anti-ErbB2 antibody-drug conjugate and composition thereof, preparation method therefor, and use thereof
[patent_app_type] => utility
[patent_app_number] => 17/169087
[patent_app_country] => US
[patent_app_date] => 2021-02-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 12
[patent_no_of_words] => 11392
[patent_no_of_claims] => 7
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 288
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17169087
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/169087 | Anti-ErbB2 antibody-drug conjugate and composition thereof, preparation method therefor, and use thereof | Feb 4, 2021 | Issued |
Array
(
[id] => 18257059
[patent_doc_number] => 20230084099
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-03-16
[patent_title] => ANTI-MEFLIN ANTIBODY FOR USE IN TREATMENT OF CANCER IN SUBJECT HAVING CANCER, AND PHARMACEUTICAL COMPOSITION COMPRISING THE ANTIBODY
[patent_app_type] => utility
[patent_app_number] => 17/759952
[patent_app_country] => US
[patent_app_date] => 2021-02-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17997
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 28
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17759952
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/759952 | ANTI-MEFLIN ANTIBODY FOR USE IN TREATMENT OF CANCER IN SUBJECT HAVING CANCER, AND PHARMACEUTICAL COMPOSITION COMPRISING THE ANTIBODY | Feb 2, 2021 | Pending |
Array
(
[id] => 17035203
[patent_doc_number] => 20210252161
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-08-19
[patent_title] => SITE SPECIFIC HOMOGENEOUS WITH KSP INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 17/166713
[patent_app_country] => US
[patent_app_date] => 2021-02-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 69539
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17166713
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/166713 | Site specific homogeneous with KSP inhibitors | Feb 2, 2021 | Issued |
Array
(
[id] => 17052236
[patent_doc_number] => 20210261670
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-08-26
[patent_title] => NOVEL ANTI-BMPR1B ANTIBODIES AND METHODS OF USE
[patent_app_type] => utility
[patent_app_number] => 17/163246
[patent_app_country] => US
[patent_app_date] => 2021-01-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 57931
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17163246
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/163246 | NOVEL ANTI-BMPR1B ANTIBODIES AND METHODS OF USE | Jan 28, 2021 | Abandoned |
Array
(
[id] => 18186338
[patent_doc_number] => 11576896
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-02-14
[patent_title] => Benzoselenophene-based compounds, pharmaceutical compositions and antibody-drug conjugates including the same
[patent_app_type] => utility
[patent_app_number] => 17/161771
[patent_app_country] => US
[patent_app_date] => 2021-01-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 3
[patent_figures_cnt] => 5
[patent_no_of_words] => 7338
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 76
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17161771
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/161771 | Benzoselenophene-based compounds, pharmaceutical compositions and antibody-drug conjugates including the same | Jan 28, 2021 | Issued |
Array
(
[id] => 18183607
[patent_doc_number] => 20230044337
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-02-09
[patent_title] => VACCINATION AGAINST ANTIGENS INDUCED IN PATHOGEN-INFECTED CELLS
[patent_app_type] => utility
[patent_app_number] => 17/759139
[patent_app_country] => US
[patent_app_date] => 2021-01-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9292
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 73
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17759139
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/759139 | VACCINATION AGAINST ANTIGENS INDUCED IN PATHOGEN-INFECTED CELLS | Jan 27, 2021 | Pending |
Array
(
[id] => 18283677
[patent_doc_number] => 20230099149
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-03-30
[patent_title] => TREATMENT OF CANCER
[patent_app_type] => utility
[patent_app_number] => 17/796707
[patent_app_country] => US
[patent_app_date] => 2021-01-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 33187
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17796707
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/796707 | Treatment of cancer | Jan 27, 2021 | Issued |
Array
(
[id] => 18620641
[patent_doc_number] => 11753669
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-09-12
[patent_title] => Lysine conjugated immunoglobulins
[patent_app_type] => utility
[patent_app_number] => 17/159655
[patent_app_country] => US
[patent_app_date] => 2021-01-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 15
[patent_figures_cnt] => 12
[patent_no_of_words] => 33269
[patent_no_of_claims] => 27
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 313
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17159655
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/159655 | Lysine conjugated immunoglobulins | Jan 26, 2021 | Issued |
Array
(
[id] => 18619192
[patent_doc_number] => 11752214
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-09-12
[patent_title] => Protein-antiviral compound conjugates
[patent_app_type] => utility
[patent_app_number] => 17/156525
[patent_app_country] => US
[patent_app_date] => 2021-01-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 13
[patent_figures_cnt] => 13
[patent_no_of_words] => 34909
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 53
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17156525
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/156525 | Protein-antiviral compound conjugates | Jan 22, 2021 | Issued |
Array
(
[id] => 18286263
[patent_doc_number] => 20230101735
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-03-30
[patent_title] => ANTI-TROP-2 ANTIDODY-EXATECAN ANALOG CONJUGATE AND MEDICAL USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/793005
[patent_app_country] => US
[patent_app_date] => 2021-01-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20383
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17793005
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/793005 | ANTI-TROP-2 ANTIDODY-EXATECAN ANALOG CONJUGATE AND MEDICAL USE THEREOF | Jan 21, 2021 | Pending |
Array
(
[id] => 18284350
[patent_doc_number] => 20230099822
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-03-30
[patent_title] => MR1 LIGANDS AND PHARMACEUTICAL COMPOSITIONS FOR IMMUNOMODULATION
[patent_app_type] => utility
[patent_app_number] => 17/793419
[patent_app_country] => US
[patent_app_date] => 2021-01-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 34299
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17793419
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/793419 | MR1 LIGANDS AND PHARMACEUTICAL COMPOSITIONS FOR IMMUNOMODULATION | Jan 17, 2021 | Abandoned |
Array
(
[id] => 20254863
[patent_doc_number] => 12427196
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-09-30
[patent_title] => Macromolecular prodrugs for light-emitting diodes and uses thereof
[patent_app_type] => utility
[patent_app_number] => 17/793276
[patent_app_country] => US
[patent_app_date] => 2021-01-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 23
[patent_figures_cnt] => 29
[patent_no_of_words] => 28524
[patent_no_of_claims] => 16
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 88
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17793276
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/793276 | Macromolecular prodrugs for light-emitting diodes and uses thereof | Jan 14, 2021 | Issued |
Array
(
[id] => 18700117
[patent_doc_number] => 11786605
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-10-17
[patent_title] => Site specific antibody-drug conjugates with peptide-containing linkers
[patent_app_type] => utility
[patent_app_number] => 17/144378
[patent_app_country] => US
[patent_app_date] => 2021-01-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 21
[patent_figures_cnt] => 21
[patent_no_of_words] => 47385
[patent_no_of_claims] => 8
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 39
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17144378
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/144378 | Site specific antibody-drug conjugates with peptide-containing linkers | Jan 7, 2021 | Issued |